Exercise and Weight Loss for Improving Mobility in Older Adults Who Are Obese (CLIP)

August 13, 2018 updated by: Wake Forest University Health Sciences

Cooperative Lifestyle Intervention Program (CLIP)

To test the effects of exercise and weight loss on mobility disability of older overweight/obese men and women who have evidence of cardiovascular disease or the metabolic syndrome.

Study Overview

Detailed Description

BACKGROUND:

Older adults make up the fastest growing segment of our population. It is estimated that by the year 2030, elderly people will make up 22% of the United States population. A large portion of older adults suffers from one or more chronic conditions that could be improved by regular physical activity. Therefore, research in this age group is needed.

DESIGN NARRATIVE:

The Cooperative Lifestyle Intervention Program (CLIP) will test the effects of a physical activity intervention and a weight loss intervention on mobility disability of overweight or obese men and women who have evidence of cardiovascular disease or the metabolic syndrome. The public health relevance of the trial lies in the fact that the interventions will be delivered in conjunction with four Cooperative Extension Centers in counties surrounding Winston-Salem, North Carolina. CLIP will be designed as a three arm, randomized, controlled trial. The three 18-month treatments will include: (1) a basic health education-based control condition, (2) a group treatment program for physical activity, and (3) a lifestyle intervention designed to reduce sedentary behavior and promote weight loss. The primary aim will be to compare the effects of the three treatment arms on the change in performance on a 400-meter walk test over the course of 18 months. Secondary aims will include changes in cardiovascular risk factors, adiposity, cardiovascular fitness, physical activity, and health-related quality of life. Analyses will also be conducted to determine whether changes in the primary outcome are mediated by changes in constructs from social cognitive theory.

Study Type

Interventional

Enrollment (Actual)

288

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Greensboro, North Carolina, United States, 27405
        • Guilford County, North Carolina Cooperative Extension Center
      • Lexington, North Carolina, United States, 27292
        • Davidson County Coopertive Extension
      • Winston-Salem, North Carolina, United States, 27105
        • Forsyth County Cooperative Extension Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 79 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Currently living in one of the counties surrounding Winston-Salem, NC
  • Sedentary (engages in fewer than 30 minutes of moderate structured physical activity for at least 10 minutes at a time each week)
  • Overweight or obese, as defined by a body mass index (BMI) greater than 25
  • Fasting glucose level less than 140
  • Documented evidence of an MI, PCTA, chronic stable angina, or cardiovascular surgery (coronary artery or valvular heart disease) within the 6 months prior to study entry or an ATP III diagnosis of the metabolic syndrome
  • Disability defined as self-reported difficulty with walking ¼ mile, climbing stairs, lifting and carrying groceries, or performing other household chores such as cleaning and yard work
  • Does not plan to move out of the county of residence for the duration of the study

Exclusion Criteria:

  • Diagnosis of bipolar depression or schizophrenia (defined as self-reported treatment for these conditions)
  • Currently receiving lithium or neuroleptics
  • Evidence of unstable angina, symptomatic congestive heart failure, or exercise-induced complex ventricular arrhythmias
  • Resting blood pressure greater than 160/100 mmHg
  • Diagnosis of any of the following: Parkinson's disease; chronic liver disease (cirrhosis, chronic hepatitis, etc.); systemic rheumatic condition (rheumatoid arthritis, psoriatic arthritis, Reiter's disease, systemic lupus erythematosus, etc.); end stage renal disease; or other systemic diseases or abnormal laboratory values which would preclude participants from safely participating in the protocol or impair their ability to complete the study
  • Actively being treated for cancer (other than non-melanotic skin cancer)
  • Significant visual or hearing impairment that cannot be corrected and results in the inability to use the telephone or hear normal conversation
  • Currently participating in or planning to participate in another medical intervention study
  • Current alcohol abuse disorder or consumes more than 21 alcoholic drinks per week
  • Unable to walk without assistance
  • Unable to speak or read English
  • Judged by the clinic staff to be unsuitable for the trial for any reason

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Health education control
This is an education program for older adults entitles, successful aging.
Lectures on information relevant to successful aging
Other Names:
  • Attention control
Experimental: Exercise Only
Structured exercise 150 min/wk
Increase Physical Activity to 150 min/wk
Other Names:
  • Physical activity
Experimental: Weight Loss
Behavioral weight loss; goal of 7%
Lose 7-10% of body weight and increase physical activity to 150 min/wk
Other Names:
  • Diet modification

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
400 meter walk
Time Frame: Measured at 18 months
Measured at 18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Walter Rejeski, Wake Forest University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2005

Primary Completion (Actual)

April 1, 2011

Study Completion (Actual)

April 1, 2011

Study Registration Dates

First Submitted

July 6, 2005

First Submitted That Met QC Criteria

July 6, 2005

First Posted (Estimate)

July 14, 2005

Study Record Updates

Last Update Posted (Actual)

August 15, 2018

Last Update Submitted That Met QC Criteria

August 13, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 197
  • R01HL076441 (U.S. NIH Grant/Contract)
  • R01HL076441-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Diseases

Clinical Trials on Health Education Control

Subscribe